These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 15844071)

  • 1. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
    Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T;
    Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J; Munsiff SS; Driver CR; Sackoff J
    Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
    Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
    Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
    Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.
    Nettles RE; Mazo D; Alwood K; Gachuhi R; Maltas G; Wendel K; Cronin W; Hooper N; Bishai W; Sterling TR
    Clin Infect Dis; 2004 Mar; 38(5):731-6. PubMed ID: 14986259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER; Joseph K
    Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
    Holland DP; Hamilton CD; Weintrob AC; Engemann JJ; Fortenberry ER; Peloquin CA; Stout JE
    Pharmacotherapy; 2009 May; 29(5):503-10. PubMed ID: 19397460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
    Weiner M; Benator D; Peloquin CA; Burman W; Vernon A; Engle M; Khan A; Zhao Z;
    Clin Infect Dis; 2005 Nov; 41(9):1343-9. PubMed ID: 16206114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(10):214-5. PubMed ID: 11922192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.
    Burman W; Benator D; Vernon A; Khan A; Jones B; Silva C; Lahart C; Weis S; King B; Mangura B; Weiner M; El-Sadr W;
    Am J Respir Crit Care Med; 2006 Feb; 173(3):350-6. PubMed ID: 16109981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
    Weiner M; Burman W; Vernon A; Benator D; Peloquin CA; Khan A; Weis S; King B; Shah N; Hodge T;
    Am J Respir Crit Care Med; 2003 May; 167(10):1341-7. PubMed ID: 12531776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does AIDS impair the absorption of antituberculosis agents?
    Taylor B; Smith PJ
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):670-5. PubMed ID: 9712282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
    Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
    Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs for tuberculosis.
    Treat Guidel Med Lett; 2004 Dec; 2(28):83-8. PubMed ID: 15557876
    [No Abstract]   [Full Text] [Related]  

  • 15. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins.
    Bonora S; Mondo A; Trentini L; Calcagno A; Lucchini A; Di Perri G
    J Infect; 2008 Jul; 57(1):78-81. PubMed ID: 18550175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.
    Kim HR; Hwang SS; Kim HJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
    Clin Infect Dis; 2007 Nov; 45(10):1290-5. PubMed ID: 17968823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
    Naiker S; Connolly C; Wiesner L; Kellerman T; Reddy T; Harries A; McIlleron H; Lienhardt C; Pym A
    BMC Pharmacol Toxicol; 2014 Nov; 15():61. PubMed ID: 25406657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival.
    Moreno S; Miralles P; Diaz MD; Baraia J; Padilla B; Berenguer J; Alberdi JC
    Arch Intern Med; 1997 Aug 11-25; 157(15):1729-34. PubMed ID: 9250234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired rifamycin resistance: pharmacology and biology.
    Wallis RS; Weyer K; Fourie PB
    Expert Rev Anti Infect Ther; 2008 Apr; 6(2):223-30. PubMed ID: 18380604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection.
    Ahmed R; Cooper R; Foisy M; Der E; Kunimoto D
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(5):273-6. PubMed ID: 22875581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.